Elanco Animal Health Incorporated $ELAN Shares Bought by Defilade Capital Management L.P.

Defilade Capital Management L.P. grew its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 132.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 931,121 shares of the company’s stock after buying an additional 529,838 shares during the quarter. Elanco Animal Health accounts for 3.1% of Defilade Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Defilade Capital Management L.P. owned about 0.19% of Elanco Animal Health worth $22,282,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. NewEdge Advisors LLC grew its stake in Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the period. Root Financial Partners LLC raised its position in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares during the period. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health during the fourth quarter worth $41,000. Torren Management LLC purchased a new position in Elanco Animal Health during the fourth quarter valued at $46,000. Finally, Bessemer Group Inc. lifted its holdings in Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after purchasing an additional 525 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of the business’s stock in a transaction on Friday, May 15th. The stock was bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rajeev A. Modi bought 4,911 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. TD Cowen raised their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Finally, Citigroup boosted their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.73.

Elanco Animal Health Trading Up 0.2%

Shares of ELAN opened at $26.42 on Monday. Elanco Animal Health Incorporated has a 52-week low of $13.39 and a 52-week high of $27.72. The stock has a market cap of $13.20 billion, a PE ratio of -52.85, a price-to-earnings-growth ratio of 1.72 and a beta of 1.68. The firm’s fifty day moving average is $24.55 and its two-hundred day moving average is $24.07. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.